DEVELOPMENT AND EVALUATION OF RANITIDINE HYDROCHLORIDE FLOATING TABLET

Floating matrix tablets of ranitidine hydrochloride were developed and evaluated to increase bioavailability by increasing gastric residence time and sustained release of drug in the upper part of gastrointestinal tract thereby diminishing side effects and enhanced patient compliance. The tablets were prepared by direct compression method, using polymers such as Hydroxy propyl methyl cellulose, carbopol 940, xanthum gum, oryza sativa husk, chitosan and cetyl alcohol. The formulations were evaluated for various physical parameters, buoyancy studies, dissolution parameters and drug released profile from all formulation batch F8 showed slow and sustained release of ranitidine hydrochloride over a period of 12 hours upto 95%. Optimized floating matrix tablets F8 showed no change in physical appearance, drug content, or in dissolution pattern after storage at 40±2°C/75±5% for 90 days. It was concluded that formulation F8 shows the better buoyancy and drug release.